Saliva-based Detection of CD44

Squamous Cell Carcinoma of the Head and Neck Clinical Trial

— Detect 44  

Official title:

A Prospective, Multi-site Trial of a Point of Care Saliva Based Detection Test Based on Soluble CD44 (OncAlert) for Presence of Disease in Previously Untreated Oral Cavity and Oropharynx Squamous Cell Carcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03148665
• Other study ID #: 161215
• Status: Completed
• Start date: April 14, 2017
• Est. completion date: May 3, 2022

Study information

• Verified date: August 2022
• Source: University of California, San Diego
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to test the ability of OncAlert™ to screen for cancer and the reappearance of cancer. OncAlert™ was developed by Vigilant Biosciences, a collaborator in this research study. OncAlert™ is an oral rinse which is spit into a cup and sent to a laboratory for analysis. OncAlert™ is considered experimental by the FDA because it is not approved for the screening of cancer.

Description:

A noninvasive point of care salivary rinse test performed as 1) a one-time test for control subjects, 2) at pretreatment and post treatment 3,6, 12, and 18 month time points in oral cavity/oropharynx cancer patients

Recruitment information / eligibility

• Status: Completed
• Enrollment: 85
• Est. completion date: May 3, 2022
• Est. primary completion date: April 10, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient has the ability to understand and the willingness to sign a written informed consent.

• Previously untreated, measurable squamous cell carcinoma of the oral cavity or oropharynx with no evidence of distant metastasis, T1-4N0-3M0

• No prior history of treated upper aerodigestive tract cancer

• No concurrent, second, active malignancy other than oral cavity and/or oropharynx cancer

• Planned to undergo treatment with curative intent

• Able to follow up after therapy at 3, 6, 12, and 18 months after completion of therapy during routine post treatment follow up

• For control subjects: no evidence or history of upper aerodigestive tract cancer

• For control subjects: absence of any suspected or confirmed active malignancy at time of enrollment

• Patients may have had prior therapy for malignancy other than upper aerodigestive malignancy completed 2 years prior to enrollment if they have been disease free since completion of therapy

• Patient is = 18 years of age.

• Both men and women of all races and ethnic groups are eligible for this trial.

• Performance Status = ECOG 3

• Patient is able to gargle and spit 5 cc of saline

• Patients may be concurrently enrolled in other therapeutic or detection clinical trials

Exclusion Criteria:

• Prior completed therapy for an upper aerodigestive tract cancer within the past 3 years.

• Patient unable to gargle and spit 5 cc of saline, or anticipated to be unable to gargle and spit after completion of therapy

• Patient unable or does not intend to undergo curative therapy

• Patient with concurrent, second primary malignancy under active therapy or completed therapy within 2 years prior to enrollment.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Oral Cavity Squamous Cell Carcinoma
• Oropharynx Squamous Cell Carcinoma
• Squamous Cell Carcinoma of Head and Neck
• Squamous Cell Carcinoma of the Head and Neck
• Squamous Cell Carcinoma of the Oropharynx

Intervention

Device:
• OncAlert
A noninvasive point of care salivary rinse test performed as 1) a one-time test for control subjects, 2) at pretreatment and post treatment 3,6, 12, and 18 month time points in oral cavity/oropharynx cancer patients

Locations

Country	Name	City	State
United States	Greater Baltimore Medical Center	Baltimore	Maryland
United States	Johns Hopkins School of Medicine	Baltimore	Maryland
United States	UCSD Moores Cancer Center	La Jolla	California
United States	New York University College of Dentistry	New York	New York

Sponsors (6)

Lead Sponsor	Collaborator
Joseph Califano	Greater Baltimore Medical Center, Johns Hopkins University, NYU Langone Health, San Diego Veterans Healthcare System, Vigilant Biosciences, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To validate performance of the Vigilant Oral Rinse Point of Care strip in a multi-institutional clinical setting	The agreement between CD44 ELISA and BCA test as measured using the POC test (OncAlert) and central laboratory testing at Vigilant The concordance of these two measures will be assessed using Cohen's kappa statistic for a dichotomized outcome (positive vs. negative test). A kappa of 0.6 or lower will be considered of insufficient concordance, and the minimum required level indicating adequate concordance is a kappa of 0.8; The sensitivity and specificity of the OncAlert test to detect OOPSCC in cases compared to a non cancer control population.; A specificity of 0.65 minimally acceptable for the Vigilant POC test. In order to demonstrate a clinically acceptable level of specificity, a performance goal of 0.75 is chosen	4 years
Secondary	To prospectively validate the performance of pretreatment Vigilant Oral Rinse Point of Care strip and Sol CD44 as a predictor of outcome for oral/oropharyngeal cancer in a point of care multi-institutional clinical setting	- The association of salivary CD44 POC test biomarkers, including both the POC test and quantitative ELISA based assay with clinical characteristics of OOPSCC patients, such as site, stage, treatment, smoking, alcohol, HPV status, and patient overall and disease free survival using univariate and multivariate analyses.	4 years
Secondary	To determine the association of post treatment salivary solCD44 and the Vigilant Oral Rinse Point of Care strip with disease outcome in oral/oropharyngeal cancer	- The association of salivary CD44 POC test biomarkers, including both the POC test and quantitative ELISA based assay with recurrence of OSCC in an OSCC population with clinical characteristics of OOPSCC patients, such as site, stage, treatment, smoking, alcohol, HPV status, and patient overall and disease free survival using univariate and multivariate analyses and determine the magnitude of that association.	4 years